@RDGLinvestors@VivosIncUSA Investors are losing confidence due to lack of transparency. We are going to 3-4s without a solid update or timeline regarding the IDE
@DailyFTdouble@VivosIncUSA The problem is the updates are too broad, not focusing on what the shareholders really want - the IDE resubmission. When recent posts reflect everything besides FDA approval and the IDE resubmission then you have a loss of faith, reflected in the stock price.
@IsoPetForCancer@VivosIncUSA Great stuff ๐ Would love to see howโs it going with the trials in India and any update on a potential IDE submission. Maybe a Q&A or a projected timeline for the remaining of 2025
@ClearUTL@VivosIncUSA I agree with this. Would much rather hear that itโs going to take longer than anticipated with transparency about whatโs going on. Instead it seems like weโre trying to distract from the IDE submission.
@Milo_DLH@RadioGel True but without pumping. This company has potential especially once we start seeing moves with their IDE submission. God willing they can resolve whatever was needed by the FDA